Geoffrey Purtill - 15 May 2022 Form 4 Insider Report for INVACARE CORP

Role
SVP & GM, EMEA & Asia Pacific
Signature
/s/ Geoffrey Purtill, by Kristofer K. Spreen, his attorney-in-fact, pursuant to Power of Attorney dated November 24, 2021, on file with the Commission
Issuer symbol
N/A
Transactions as of
15 May 2022
Net transactions value
-$1,746
Form type
4
Filing time
17 May 2022, 17:09:07 UTC
Previous filing
03 Dec 2021
Next filing
15 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IVC Common Shares Tax liability $1,746 -1,602 -2.7% $1.09* 57,752 15 May 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IVC Employee Stock Option (Right to Buy) 25,911 15 May 2022 Common Shares 25,911 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The surrender of these shares is for tax withholding purposes in conjunction with the vesting of restricted stock units held by the reporting person.
F2 Includes 9,105 previously reported restricted stock units issued pursuant to the Invacare Corporation 2018 Equity Compensation Plan. 1,425 of these restricted stock units vest in full on May 15, 2023; 2,680 of these restricted stock units vest in 1/2 increments on May 15, 2023 and May 15, 2024; and 5,000 of these restricted stock units vest in 1/3 increments on November 15, 2022, November 15, 2023 and November 15, 2024.
F3 No transaction is being reported on this line. Reported on previously filed Form 3.
F4 The reporting person holds previously reported options to buy 25,911 Common Shares (with tandem tax withholding rights) under the Invacare Corporation 2003 Performance Plan and the Invacare Corporation 2013 Equity Compensation Plan, granted in reliance upon the exemption provided by Rule 16b-3. All options were granted between August 14, 2012 and March 16, 2017, at exercise prices between $12.15 and $14.49 per share, will expire between August 14, 2022 and March 16, 2027, and became exercisable between September 30, 2013 and December 31, 2019.